Scalper1 News
Four big-cap drugmakers reported mostly solid first quarters Thursday morning, but the market gave them a decidedly mixed reception. Israeli generic-drug giant Teva Pharmaceutical (TEVA) reported earnings minus one-time items of $1.36 a share, up 11.5% from the year-earlier quarter and beating analyst consensus by 11 cents, according to Thomson Reuters. Sales declined a fraction to $4.98 billion, but beat Street estimates by $150 million. Scalper1 News
Scalper1 News